FDA Approves 3-Times-a-Week Copaxone in MSFDA Approves 3-Times-a-Week Copaxone in MS

On the basis of results of the GALA trial, the FDA has approved a higher-dose, lower-frequency regimen of glatiramer acetate, the company announced. FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news